247 related articles for article (PubMed ID: 36154176)
21. Drug-induced acne with elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
Hudson BN; Jacobs HR; Philbrick A; Zhou XA; Simonsen MM; Safirstein JA; Rotolo SM
J Cyst Fibros; 2022 Nov; 21(6):1066-1069. PubMed ID: 36088208
[TBL] [Abstract][Full Text] [Related]
22. The Rapid Reduction of Infection-Related Visits and Antibiotic Use Among People With Cystic Fibrosis After Starting Elexacaftor-Tezacaftor-Ivacaftor.
Miller AC; Harris LM; Cavanaugh JE; Abou Alaiwa M; Stoltz DA; Hornick DB; Polgreen PM
Clin Infect Dis; 2022 Sep; 75(7):1115-1122. PubMed ID: 35142340
[TBL] [Abstract][Full Text] [Related]
23. Elexacaftor/tezacaftor/ivacaftor improves chronic rhinosinusitis detected by magnetic resonance imaging in children with cystic fibrosis on long-term therapy with lumacaftor/ivacaftor.
Wucherpfennig L; Becker JKZ; Wuennemann F; Eichinger M; Seitz A; Baumann I; Stahl M; Graeber SY; Zhao S; Chung J; Schenk JP; Alrajab A; Kauczor HU; Mall MA; Sommerburg O; Wielpütz MO
J Cyst Fibros; 2024 Mar; 23(2):234-241. PubMed ID: 38218661
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial.
Sutharsan S; McKone EF; Downey DG; Duckers J; MacGregor G; Tullis E; Van Braeckel E; Wainwright CE; Watson D; Ahluwalia N; Bruinsma BG; Harris C; Lam AP; Lou Y; Moskowitz SM; Tian S; Yuan J; Waltz D; Mall MA;
Lancet Respir Med; 2022 Mar; 10(3):267-277. PubMed ID: 34942085
[TBL] [Abstract][Full Text] [Related]
25. Clinical efficacy of elexacaftor-tezacaftor-ivacaftor in an adolescent with homozygous G85E cystic fibrosis.
Stekolchik E; Saul D; Chidekel A
Respir Med Case Rep; 2022; 40():101775. PubMed ID: 36411821
[TBL] [Abstract][Full Text] [Related]
26. Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis.
Marshall LZ; Espinosa R; Starner CI; Gleason PP
J Manag Care Spec Pharm; 2023 Jun; 29(6):599-606. PubMed ID: 37276039
[No Abstract] [Full Text] [Related]
27. Rescue of chloride and bicarbonate transport by elexacaftor-ivacaftor-tezacaftor in organoid-derived CF intestinal and cholangiocyte monolayers.
Bijvelds MJC; Roos FJM; Meijsen KF; Roest HP; Verstegen MMA; Janssens HM; van der Laan LJW; de Jonge HR
J Cyst Fibros; 2022 May; 21(3):537-543. PubMed ID: 34922851
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Heijerman HGM; McKone EF; Downey DG; Van Braeckel E; Rowe SM; Tullis E; Mall MA; Welter JJ; Ramsey BW; McKee CM; Marigowda G; Moskowitz SM; Waltz D; Sosnay PR; Simard C; Ahluwalia N; Xuan F; Zhang Y; Taylor-Cousar JL; McCoy KS;
Lancet; 2019 Nov; 394(10212):1940-1948. PubMed ID: 31679946
[TBL] [Abstract][Full Text] [Related]
29. Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients.
Doligalski CT; McKinzie CJ; Yang A; Lobo LJ; Coakley R
Pharmacotherapy; 2022 Jul; 42(7):580-584. PubMed ID: 35689451
[TBL] [Abstract][Full Text] [Related]
30. Impact of elexacaftor/tezacaftor/ivacaftor on vitamin D absorption in cystic fibrosis patients.
Wright BA; Ketchen NK; Rasmussen LN; Bartels AR; Singh SB
Pediatr Pulmonol; 2022 Mar; 57(3):655-657. PubMed ID: 34859619
[TBL] [Abstract][Full Text] [Related]
31. Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor-Ivacaftor.
Tümmler B
Front Pharmacol; 2023; 14():1158207. PubMed ID: 37025483
[TBL] [Abstract][Full Text] [Related]
32. Structural changes in lung morphology detected by MRI after modulating therapy with elexacaftor/tezacaftor/ivacaftor in adolescent and adult patients with cystic fibrosis.
Fainardi V; Skenderaj K; Ciuni A; Milanese G; Deolmi M; Longo F; Spaggiari C; Sverzellati N; Esposito S; Pisi G
Respir Med; 2023 Sep; 216():107328. PubMed ID: 37321310
[TBL] [Abstract][Full Text] [Related]
33. Long-term clinical outcomes of elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis and advanced pulmonary disease.
Savi D; Lucca F; Tridello G; Meneghelli I; Comello I; Tomezzoli S; Signorini M; Proietti E; Cucchetto G; Volpi S; Cipolli M
Respir Med; 2023; 219():107406. PubMed ID: 37690570
[TBL] [Abstract][Full Text] [Related]
34. Effects of Elexacaftor/Tezacaftor/Ivacaftor on Cardiorespiratory Polygraphy Parameters and Respiratory Muscle Strength in Cystic Fibrosis Patients with Severe Lung Disease.
Giallongo A; Parisi GF; Papale M; Manti S; Mulé E; Aloisio D; Terlizzi V; Rotolo N; Leonardi S
Genes (Basel); 2023 Feb; 14(2):. PubMed ID: 36833376
[TBL] [Abstract][Full Text] [Related]
35. Improved glucose tolerance after initiation of Elexacaftor / Tezacaftor / Ivacaftor in adults with cystic fibrosis.
Steinack C; Ernst M; Beuschlein F; Hage R; Roeder M; Schuurmans MM; Schmid C; Gaisl T
J Cyst Fibros; 2023 Jul; 22(4):722-729. PubMed ID: 36669960
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease.
Terlizzi V; Colangelo C; Marsicovetere G; D'Andria M; Francalanci M; Innocenti D; Masi E; Avarello A; Taccetti G; Amato F; Comegna M; Castaldo G; Salvatore D
Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440351
[TBL] [Abstract][Full Text] [Related]
37. Acneiform Eruption Following Elexacaftor-Tezacaftor-Ivacaftor Treatment in Patients With Cystic Fibrosis.
Okroglic L; Sohier P; Martin C; Lheure C; Franck N; Honoré I; Kanaan R; Burgel PR; Carlotti A; Dupin N; Oulès B
JAMA Dermatol; 2023 Jan; 159(1):68-72. PubMed ID: 36449298
[TBL] [Abstract][Full Text] [Related]
38. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials.
He R; Lin F; Deng Z; Yu B
SAGE Open Med; 2024; 12():20503121231225874. PubMed ID: 38249954
[TBL] [Abstract][Full Text] [Related]
39. Longitudinal Profiling of the Intestinal Microbiome in Children with Cystic Fibrosis Treated with Elexacaftor-Tezacaftor-Ivacaftor.
Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
medRxiv; 2023 Nov; ():. PubMed ID: 37645804
[TBL] [Abstract][Full Text] [Related]
40. Triple Therapy for Cystic Fibrosis
Barry PJ; Mall MA; Álvarez A; Colombo C; de Winter-de Groot KM; Fajac I; McBennett KA; McKone EF; Ramsey BW; Sutharsan S; Taylor-Cousar JL; Tullis E; Ahluwalia N; Jun LS; Moskowitz SM; Prieto-Centurion V; Tian S; Waltz D; Xuan F; Zhang Y; Rowe SM; Polineni D;
N Engl J Med; 2021 Aug; 385(9):815-825. PubMed ID: 34437784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
